WO2013005603A9 - Agent pour la prévention et/ou le traitement d'une inflammation allergique de la conjonctive - Google Patents

Agent pour la prévention et/ou le traitement d'une inflammation allergique de la conjonctive Download PDF

Info

Publication number
WO2013005603A9
WO2013005603A9 PCT/JP2012/066207 JP2012066207W WO2013005603A9 WO 2013005603 A9 WO2013005603 A9 WO 2013005603A9 JP 2012066207 W JP2012066207 W JP 2012066207W WO 2013005603 A9 WO2013005603 A9 WO 2013005603A9
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptide
conjunctiva
allergic
sema3a
semaphorin
Prior art date
Application number
PCT/JP2012/066207
Other languages
English (en)
Japanese (ja)
Other versions
WO2013005603A1 (fr
Inventor
純美 田中
信久 水木
良郎 五嶋
Original Assignee
公立大学法人横浜市立大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 公立大学法人横浜市立大学 filed Critical 公立大学法人横浜市立大学
Publication of WO2013005603A1 publication Critical patent/WO2013005603A1/fr
Publication of WO2013005603A9 publication Critical patent/WO2013005603A9/fr

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Definitions

  • An object of the present invention is to provide eye drops and subconjunctival injections for intractable allergic conjunctival diseases including seasonal allergic conjunctivitis.
  • the active ingredient polypeptide a may be composed only of the polypeptide (a) as long as it has preventive and / or therapeutic activity for allergic inflammation in the conjunctiva, and may be one end of the polypeptide (a). Alternatively, an amino acid or polypeptide added at both ends may be used.
  • Sema3A lacking the Ig domain also has DRG regression activity (Koppel et al., 1997), but such a polypeptide is also present in the region of Sema3A containing 70aa at the N-terminal side of the Ig domain.
  • a polypeptide to which a basic domain is added is included in the active ingredient polypeptide a and is within the scope of the present invention.
  • the specific examples described above are merely examples, and any amino acid or polypeptide added to the polypeptide (a) can be used as long as it has preventive and / or therapeutic activity for allergic inflammation in the conjunctiva.
  • the active ingredient polypeptide a is included in the scope of the present invention.
  • Semaphorin 3A used as an active ingredient in the present invention can be easily prepared by a conventional method using, for example, a commercially available peptide synthesizer. Moreover, it can prepare easily using a well-known genetic engineering method. For example, a Sema3A gene cDNA is prepared by RT-PCR from RNA extracted from a tissue expressing the Sema3A gene, and the full length or a desired part of the cDNA is incorporated into an expression vector and introduced into a host cell. The desired polypeptide can be obtained. RNA extraction, RT-PCR, cDNA integration into a vector, and introduction of a vector into a host cell can be performed by known methods.
  • Semaphorin 3A which is an active ingredient in the preventive and / or therapeutic agent of the present invention, is effective in treating and / or preventing allergic inflammation in the conjunctiva.
  • Allergic inflammation in the conjunctiva includes eosinophilic conjunctival disease, allergic conjunctivitis (including seasonal allergic conjunctivitis such as pollen conjunctivitis), allergic keratoconjunctivitis, allergic blepharitis, hay fever, atopic keratoconjunctivitis Semaphorin 3A is useful for preventive initial treatment (therapy) of these diseases, pre-seasonal administration and / or therapeutic agent conservative treatment, maintenance therapy / induction therapy. is there.
  • the count section was the range including the pupil and optic disc from the center. Data were examined as mean ⁇ standard error of all mice, one-way analysis of variance and Tukey-Kramer multiple comparison test.
  • Mouse conjunctiva was frozen in liquid nitrogen embedded in OCT compound (VWR, Sawanee, GA, USA). This was prepared and fixed with methanol.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des gouttes ophtalmiques, et un médicament d'injection sous-conjonctivale pour une maladie conjonctivale allergique réfractaire, avant tout pour la conjonctivite allergique saisonnière. Cet agent pour la prévention et/ou le traitement d'une inflammation allergique dans la conjonctive contient de la sémaphorine-3A comme principe actif.
PCT/JP2012/066207 2011-07-01 2012-06-26 Agent pour la prévention et/ou le traitement d'une inflammation allergique de la conjonctive WO2013005603A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011147038 2011-07-01
JP2011-147038 2011-07-01

Publications (2)

Publication Number Publication Date
WO2013005603A1 WO2013005603A1 (fr) 2013-01-10
WO2013005603A9 true WO2013005603A9 (fr) 2013-04-04

Family

ID=47436958

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2012/066207 WO2013005603A1 (fr) 2011-07-01 2012-06-26 Agent pour la prévention et/ou le traitement d'une inflammation allergique de la conjonctive

Country Status (1)

Country Link
WO (1) WO2013005603A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014178427A1 (fr) * 2013-05-02 2014-11-06 学校法人順天堂 Procede pour controler l'expression de la semaphorine 3a
JP6440107B2 (ja) * 2014-03-03 2018-12-19 国立大学法人 東京大学 細胞シートの製造方法、組成物、細胞培養補助剤、及び細胞培養方法
US10736939B2 (en) 2015-02-10 2020-08-11 Medical Research & Development Fund for Health Services Bnai Zion Medical Center Semaphorin 3A for treatment and assessment of severity of inflammatory bowel disease
AR122266A1 (es) 2019-05-09 2022-08-31 Boehringer Ingelheim Int Anticuerpos anti-sema3a y sus usos para tratar enfermedades oculares
JPWO2023032994A1 (fr) * 2021-08-31 2023-03-09

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008107275A (ja) * 2006-10-27 2008-05-08 Juntendo アレルギー性皮膚炎の診断法
JP4581115B2 (ja) * 2007-05-31 2010-11-17 公立大学法人横浜市立大学 そう痒性皮膚疾患の治療又は予防剤

Also Published As

Publication number Publication date
WO2013005603A1 (fr) 2013-01-10

Similar Documents

Publication Publication Date Title
US11738064B2 (en) Pharmaceutical composition for preventing and treating eye diseases, containing as active ingredient, fusion protein in which tissue-penetrating peptide and anti-vascular endothelial growth factor preparation are fused
EP2968471B1 (fr) Peptides destinés à être utilisés dans le traitement topique de maladies neurodégénératives rétiniennes, en particulier dans les stades précoces de la rétinopathie diabétique et d'autres maladies rétiniennes dans lesquelles la neurodégénérescence joue un rôle essentiel
US20130231464A1 (en) Methods of use of soluble cd24 for therapy of rheumatoid arthritis
US9233140B2 (en) Treatment methods for hypersensitive disorders
WO2013005603A9 (fr) Agent pour la prévention et/ou le traitement d'une inflammation allergique de la conjonctive
US20210386837A1 (en) Active low molecular weight variants of angiotensin converting enzyme 2 (ace2) for the treatment of diseases and conditions of the eye
JP2007529418A (ja) Ｖｅｇｆアンタゴニストの使用による角膜移植拒絶を処置する方法
US20190002517A1 (en) Neuropeptide y-derived peptides
JP6440107B2 (ja) 細胞シートの製造方法、組成物、細胞培養補助剤、及び細胞培養方法
JP6033433B2 (ja) アポリポタンパク質ａｉｖを用いて高血糖障害を治療する方法
Castro et al. Low-dose melittin is safe for intravitreal administration and ameliorates inflammation in an experimental model of uveitis
US20140038887A1 (en) Glial cell line derived neurotrophic factor, obesity, and obesity-related diseases and conditions
CN114945387A (zh) 包含作为活性成分的Prox1抑制剂的用于预防或治疗视网膜神经变性疾病的药物组合物
US10052362B2 (en) Glial cell line derived neurotrophic factor, obesity, and obesity-related diseases and conditions
Wilke et al. Complement regulation in the eye: implications for age-related macular degeneration
WO2014202834A1 (fr) Protamine pour le traitement de lésions neuronales
US20220211810A1 (en) Method of Treatment
KR20220000357A (ko) Prox1 기능 억제제를 유효성분으로 포함하는, 망막신경 퇴행성 질환의 예방 또는 치료용 약학적 조성물
Jones The Role of Fibrillin-1 in Eye Development and Disease
Lee et al. https://www. jbc. org/cgi/doi/10.1074/jbc. RA120. 016053 The latest version is at
US20160331807A1 (en) Therapeutic use of vegfr-3 ligands
Class et al. Patent application title: NEUROPEPTIDE Y-DERIVED PEPTIDES Inventors: David Paul D. Woldbye (CopenhagenØ, DK) Casper Rene Gøtzsche (Copenhagen Ø, DK) Kristian Klemp (Charlottenlund, DK) Vladimir Berezin (Copenhagen N, DK) Vladimir Berezin (Copenhagen N, DK) Elisabeth Bock (Charlottenlund, DK)
BR112015020143B1 (pt) Composição tópica farmacêutica no tratamento ocular tópico e/ou na prevenção de doenças neurodegenerativas da retina

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12807502

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12807502

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: JP